News & Updates

The combination of ivosidenib and azacitidine (IVO-AZA) improves event-free and overall survival (OS) vs AZA alone in patients with acute myeloid leukaemia (AML) bearing somatic mutations in isocitrate dehydrogenase 1 (IDH1), the AGILE trial has shown.

While getting vaxxed remains the best protection against severe COVID-19, severe breakthrough infections are still possible, particularly in patients with haematological malignancies, a registry-based study has shown.

Wristband actigraphy devices, through the help of deep-learning prediction models, can predict survival outcomes in end-stage cancer patients on palliative care, according to a recent study.

Adjuvant treatment with metformin does not improve outcomes in most patients with early breast cancer in a phase III study, suggesting that metformin should not be used as a breast cancer treatment in these patients.

In patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) who respond to first-line induction therapy with panitumumab plus fluorouracil, folinic acid and oxaliplatin (FOLFOX), maintenance panitumumab plus fluorouracil and folinic acid (FU/FA) significantly improves progression-free survival (PFS) vs FU/FA alone, results of the PANAMA trial have shown.